• Sci Transl Med · May 2021

    The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

    • Bryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, Kathryn Westendorf, Julian Davies, Thomas P Cujec, Christopher M Wiethoff, Jamie L Blackbourne, Beverly A Heinz, Denisa Foster, Richard E Higgs, Deepa Balasubramaniam, Lingshu Wang, Yi Zhang, Eun Sung Yang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, Kevin R Jepson, Rodrigo Goya, Maia A Smith, David W Collins, Samuel J Hinshaw, Sean A Tycho, Davide Pellacani, Ping Xiang, Krithika Muthuraman, Solmaz Sobhanifar, Marissa H Piper, Franz J Triana, Jorg Hendle, Anna Pustilnik, Andrew C Adams, Shawn J Berens, Ralph S Baric, David R Martinez, Robert W Cross, Thomas W Geisbert, Viktoriya Borisevich, Olubukola Abiona, Hayley M Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, Marie I Samanovic, Mark J Mulligan, Jory A Goldsmith, Ching-Lin Hsieh, Nicole V Johnson, Daniel Wrapp, Jason S McLellan, Bryan C Barnhart, Barney S Graham, John R Mascola, Carl L Hansen, and Ester Falconer.
    • Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA. jones_bryan_edward@lilly.com ester.falconer@abcellera.com.
    • Sci Transl Med. 2021 May 12; 13 (593).

    AbstractSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour-1 kg-1, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…